The company this decision after consultation with the EMEA in view of the Iressa Survival Evaluation in Lung Cancer survival not met not met, the admissions requirements for the current IRESSA MAA. The submission of a new MAA will be taken for Iressa in the future into consideration, according to the evaluation of the overall ISEL dataset and emerging data.
AstraZeneca is a major international healthcare business in the research, development, manufacture and marketing of prescription pharmaceuticals and healthcare services deals. It is one of of the world’s leading pharmaceutical companies with sales of more than $ 18800000000 and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. FTSE4Good Index.ed in the Dow Jones Sustainability Index as well as the FTSE4Good Index.Approximately Final FDA approval of generic Solodyn Extended-Release Tablets, 90 mg and 135 mg.
How already on 1 December 2008 announced IMPAX and Medici stepped into a settlement and Stock agreement under which IMPAX a license to of its generic versions of Solodyn 45mg, 90 mg and 135mg by Global Pharmaceuticals, IMPAX the generic market division, under the Solodyn intellectual property belong Medici, the latest November 2011. Following the introduction of generic terms Solodyn , IMPAX is to pay Medici described a royalty on revenues of such generic formulations IMPAX under conditions of settlements and license agreement base.